Previous Close | 43.70 |
Open | N/A |
Bid | 49.70 |
Ask | 54.20 |
Strike | 150.00 |
Expire Date | 2024-07-19 |
Day's Range | 43.70 - 43.70 |
Contract Range | N/A |
Volume | |
Open Interest | 1 |
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Novartis (NVS) reports phase III data that confirm sustained efficacy and long-term safety of oral remibrutinib in chronic spontaneous urticaria.